Evidence map›Paper›PMID 40831701›Full record

ReviewFrontiers in cellular and infection microbiology2025

Towards the elimination of infectious HPV: exploiting CRISPR/Cas innovations.

Wei Liu, Yingyan Jiang, Cheng Wang, Min Wang, Wei Zhang, Haiying Ren, Shiyan Xu, Jinjing Qin, Pan Liu, Lianhai Jin and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wei Liu *College of Laboratory Medicine, Jilin Medical University, Jilin, China.
Yingyan Jiang *Department of Obstetrics and Gynecology, Affiliated hospital of Jilin medical university, Jilin, China.
Cheng Wang *College of Basic Medicine, Jilin Medical University, Jilin, China.
Min WangDepartment of Obstetrics and Gynecology, The Second Hospital of Jilin University, Changchun, China.
Wei ZhangLow Pressure and Low Oxygen Environment and Health Intervention Innovation Center, Jilin Medical University, Jilin, China.
Haiying RenPsychiatric Research Unit III, Jilin Sixth People's Hospital, Jilin, China.
Shiyan XuCollege of Laboratory Medicine, Jilin Medical University, Jilin, China.
Jinjing QinCollege of Laboratory Medicine, Jilin Medical University, Jilin, China.
Pan LiuCollege of Laboratory Medicine, Jilin Medical University, Jilin, China.
Lianhai JinLow Pressure and Low Oxygen Environment and Health Intervention Innovation Center, Jilin Medical University, Jilin, China.
Donghai ZhaoCollege of Basic Medicine, Jilin Medical University, Jilin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HPV has been conclusively associated with various human malignancies, making the development of prevention and treatment strategies for HPV-induced diseases a high priority. Currently, primary prevention methods include HPV immunization and routine screening, which significantly reduce the risk of HPV transmission. However, for patients diagnosed with invasive, advanced, or recurrent malignancies, non-virus-specific therapies frequently lead to drug resistance and adverse effects, resulting in minimal improvement in treatment efficacy for numerous patients. Viral genome-targeting therapy is emerging as a promising avenue for the future management of HPV infections. With the rapid advancement of genetic modification technologies, the CRISPR/Cas system has demonstrated significant potential in treating viral infections. Its ability to selectively target and edit viral genomes for elimination positions it as a highly effective approach for combating HPV. This review will explore the functions and applications of the CRISPR/Cas system as an innovative therapy for HPV. We will illustrate the prospective efficacy of CRISPR/Cas as a groundbreaking and promising cure for HPV infections, while also addressing the opportunities and challenges associated with this novel approach.

Indexed as

CRISPR-Cas SystemsGene EditingGenetic TherapyPapillomaviridaePapillomavirus InfectionsGenome, ViralHumansCRISPR/Casgene editingHPVHPV-associated diseasesviral genome targeting therapy

Identifiers

PMID40831701
PMCPMC12358359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.